1. Hong Kong Stocks

  2. •

    Finance

  3. •

    Finance/Rental/Leasing
Zhong Ji Longevity Science Group Limited

Zhong Ji Longevity Science Group Limited

HHKEX:767
0.49
HKD
0.00
(0.00%)
122.97MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.24
0.23
0.37
1.62
0.71
0.47
0.38
0.05
0.04
0.06
0.04
0.2
0.27
- -
Basic EPS, GAAP
0.6
-0.09
-0.53
0.94
0.21
-5.68
-2.13
-0.01
- -
- -
- -
-0.04
-0.03
- -
Free Cash Flow per Basic Share
-0.79
-0.46
-0.32
0.13
-0.28
0.48
-0.05
-0.14
-0.03
0.01
0.01
-0.07
-0.04
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
3.56
5.44
14.84
10.5
10.74
3.98
2.44
1.11
1.15
0.93
0.89
0.68
0.62
0.68
Tangible Book Value per Share
2.46
4.57
6.99
4.86
5.1
3.98
2.44
1.11
1.15
0.93
0.89
0.68
0.62
0.68
Basic Weighted Avg Shares
125
278
278
342
387
387
387
1,478
1,478
1,517
1,547
836
593
507
Sales/Revenue/Turnover
30
65
102
555
273
180
146
80
61
90
65
166
162
- -
Operating Margin (%)
-29.06
60.89
31.39
70.6
50.53
45.62
63.9
-18.36
16.18
13.5
-37.96
-5.68
-15.15
- -
Depreciation Expense
1
1
1
4
1
3
4
2
4
4
7
7
6
- -
Net Income, GAAP
76
-26
-148
322
82
-2,199
-826
-11
6
-1
2
-35
-17
- -
Effective Tax Rate (%)
- -
- -
- -
21.14
32.04
- -
- -
- -
10.92
92.48
46.83
- -
- -
- -
Profit Margin (%)
254.6
-39.91
-144.68
57.96
30.1
-1,221.39
-566.13
-14.35
9.91
-1.01
3.56
-20.9
-10.36
- -
Working Capital
420
474
807
1,176
1,245
1,039
299
156
232
246
250
372
399
372
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
4
3
3
3
Total Equity
992
1,512
4,135
4,081
4,180
1,567
967
455
471
421
430
400
425
400
Return on Invested Capital (%)
8.71
- -
- -
7.77
2.26
- -
- -
- -
1.89
0.19
0.62
- -
- -
- -
Return on Capital (%)
8.74
- -
- -
7.56
1.87
- -
- -
- -
1.38
-0.54
0.71
- -
- -
- -
Return on Common Equity (%)
8.99
-2.08
-5.26
7.86
2
-77.19
-66.48
-1.68
1.39
-0.22
0.58
-8.94
-4.34
- -

Capital Structure

HKD

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
ST Debt
16
16
16
LT Borrowings
- -
- -
- -
LT Finance Leases
4
1
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
455
547
547
Market Capitalization
61
169
123

Working Capital

HKD

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
Total Current Assets
323
320
494
Cash, Cash Equivalents & STI
81
79
48
Accounts Receivable, Net
2
2
72
Inventories
3
1
1
Total Current Liabilities
73
65
122
Payables & Accruals
- -
- -
- -
ST Debt
16
16
16
Deferred Revenue
- -
- -
- -

Growth Rates

HKD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-15.83%
-1.13%
6.21%
Free Cash Flow
-57.55%
-143.27%
-62.55%
Net Income, GAAP
-560.21%
-455.32%
-51.76%
Sales/Revenue/Turnover
44.15%
29.72%
-2.66%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
65
2024
- -
- -
166
2025
- -
- -
162

Semi-annual Earnings Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
-0.04
2025
- -
- -
-0.03

Semi-annual Dividends Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Li Yan
Full Time Employees
43
Sector
Finance
Industry
Finance/Rental/Leasing
Address
606, 6/F Hong Kong Hong Kong
IPO Date
Nov 20, 1995
Website
irasia.com
Similar Companies
SoFi Technologies, Inc. (NASDAQ:SOFI)
Visa Inc. (NYSE:V)
Bajaj Finance Limited (NSE:BAJFINANCE)
Mastercard Incorporated (NYSE:MA)
American Express Company (NYSE:AXP)
One 97 Communications Ltd. (NSE:PAYTM)
Business
Zhong Ji Longevity Science Group Limited (0767.HK), an investment holding company incorporated in Bermuda in 1994 and headquartered in Kowloon Bay, Hong Kong, principally engages in longevity science and money lending businesses in Hong Kong and Mainland China. The company operates through five main segments: Longevity Science, encompassing research, medical testing, biological products such as NMN and vitamin C sustained-release tablets, management services, and membership divisions; Money Lending and Financial Advisory, providing credits and consulting; Securities and Other Investments, holding equity and financial assets; Property Investment, for rental income and capital appreciation; and health consulting with medical product trading. It offers diagnostic consultations, cancer prevention and immunity supplements, longevity wine distribution, and healthcare testing services targeting high-net-worth individuals and health-focused markets. Recent developments include the appointment of Mr. Yan Li as executive chairman and CEO effective October 17, 2025, following resignations of prior executives; a collaboration agreement signed September 13, 2025, with Hainan Boao Super Hospital to establish an International Precision Oncology Medical Center; a memorandum of understanding with China International Osteoarticular Medical Group for acquiring Asian Integrated Cell Laboratory to advance cell therapies for cancer prevention, anti-aging, and knee health; an announced acquisition of 25% stake in Asian Integrated Cell Laboratory for HK$300 million as of December 1, 2025; and a July 29, 2025, memorandum of cooperation with Haoshiduo to enhance diagnostics and medical services.